Restore Mind Medicine

External R&D Collaborations See Company SEC Filings, MindMed.co We believe that MindMed's external R&D collaborations with UHB are critical to providing MindMed with a competitive advantage on new research molecules and data to expand the pipeline. In 2022, MindMed took the short-sighted approach and slashed external R&D collaborations from $4.2M to $1.9M. Namely, this effects the UHB collaboration who is performing 9 out of 10 the active trials. We intend to restore external R&D spending to pre-2022 levels to ensure that UHB is well resourced to provide quality clinical data. 75

View entire presentation